Loading…
Counterfeit Drug Prevention Act of 2009
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
77pct
47d open
vs 6,490 other HR bills in the 111th — cohort avg 44d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2010 · first_quarter · Pharmacy
**see addendum page Importation of prescription drugs (S. 525/H.R. 1298) RX Pedigree Import Safety (H.R. 759) Counterfeit Drugs (H.R. 1450) Methamphetamine / Pseudoephedrine Regulation (S. 256) Dextromethorphan Regulation (H.R. 1259) Pharmacy Benefit Management Issues (H.R. 4489)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · first_quarter · Pharmacy
Importation of prescription drugs (S. 525/H.R. 1298), Import Safety (H.R. 759), Rx Pedigree, Counterfeit Drugs (H.R. 1450), Methamphetamine/Pseudoephedrine Regulation (S. 256), Pharmacy Benefit Management (PBM) issues (H.R. 4489)
Client expense: $190,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2009 · fourth_quarter · Pharmacy
H.R.1, the American Recovery and Reinvestment Act, as related to health information technology and state Medicaid programs. H.R. 1259, the Dextromethorphan Distribution Act, as related to the abuse of dextromethorphan. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, as related to the approval of generic biopharmaceuticals. S. 726, Promoting Innovation and Access to Life-Saving Medicine Act, as related to the approval of generic biopharmaceuticals. H.R.616/S.511, Access to Durable Medical Equipment Act, related to the exemption of pharmacies from Medicare accreditation requirements. H.R.759, Food and Drug Administration Globalization Act of 2009, as related to the safety of prescription drugs. H.R. 1191/S.1336, Safe Drug Disposal Act of 2009, as related to the role of pharmacy in the disposal of prescription drugs. H.R. 1256, the Family Smoking Prevention and Tobacco Control Act, as related to the importation of prescription drugs. H.R. 1298/S.525,S.1232, Pharmaceutical Market Access and Drug Safety Act, as related to the importation of prescription drugs. H.R. 1359, Secure and Responsible Drug Disposal Act of 2009, as related to the role of pharmacy in the disposal of prescription drugs. H.R. 1450, Counterfeit Drug Prevention Act of 2009, as related to the prosecution of prohibited acts related to prescription drugs. H.R. 1548, Pathway for Biosimilars Act, as related to the approval of generic biopharmaceuticals by the FDA. H.R. 1970/S.956, Preserve Patient Access to Reputable DMEPOS Providers Act of 2009, as related to pharmacy exemption from the Medicare Bart B surety bond requirement. H.R. 2221, Data Accountability and Trust Act, related to the use of prescription drug data by pharmacies. H.R. 2552, Medical Waste Management Act of 2009, as related to the role of pharmacy in the disposal of prescription drugs. H.R. 2923/S.256, Combat Methamphetamine Enhancement Act, as related to the abuse of methamphetamine. H.R. 2997/S.1406, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010, as related to the importation of prescription drugs. H.R. 3108, the Medication Therapy Management Benefits Act, as related to an expanded MTM program in the Medicare Part D program. H.R. 3200, America's Affordable Health Choices Act of 2009, related to changes in pharmacy Medicaid reimbursement and the role of pharmacy and pharmacists in healthcare reform. H.R. 3590, Patient Protection and Affordable Care Act, as related to the role of pharmacy in healthcare reform, specifically related to Medicare and Medicaid issues. H.R. 3663, as related to the delay of pharmacy accreditation requirements under the Medicare DME Program. H.R.3962, Affordable Health Care for America Act, as related to the role of pharmacy in healthcare reform, specifically related to Medicare and Medicaid issues. S.1383, Dextromethorphan Abuse Reduction Act, as related to the abuse of dextromethorphan.
Client expense: $450,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Consumer Product Safety Commission (CPSC), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, White House Office
2009 · third_quarter · Pharmacy
H.R.1, the American Recovery and Reinvestment Act, as related to health information technology and state Medicaid programs. H.R. 1259, the Dextromethorphan Distribution Act, as related to the abuse of dextromethorphan. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, as related to the approval of generic biopharmaceuticals. S. 726, Promoting Innovation and Access to Life-Saving Medicine Act, as related to the approval of generic biopharmaceuticals. H.R.616/S.511, Access to Durable Medical Equipment Act, related to the exemption of pharmacies from Medicare accreditation requirements. H.R.759, Food and Drug Administration Globalization Act of 2009, as related to the safety of prescription drugs. H.R. 1191/S.1336, Safe Drug Disposal Act of 2009, as related to the role of pharmacy in the disposal of prescription drugs. H.R. 1256, the Family Smoking Prevention and Tobacco Control Act, as related to the importation of prescription drugs. H.R. 1298/S.525,S.1232, Pharmaceutical Market Access and Drug Safety Act, as related to the importation of prescription drugs. H.R. 1359, Secure and Responsible Drug Disposal Act of 2009, as related to the role of pharmacy in the disposal of prescription drugs. H.R. 1450, Counterfeit Drug Prevention Act of 2009, as related to the prosecution of prohibited acts related to prescription drugs. H.R. 1548, Pathway for Biosimilars Act, as related to the approval of generic biopharmaceuticals by the FDA. H.R. 1970/S.956, Preserve Patient Access to Reputable DMEPOS Providers Act of 2009, as related to pharmacy exemption from the Medicare Bart B surety bond requirement. H.R. 2552, Medical Waste Management Act of 2009, as related to the role of pharmacy in the disposal of prescription drugs. H.R. 2923/S.256, Combat Methamphetamine Enhancement Act, as related to the abuse of methamphetamine. H.R. 2997/S.1406, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010, as related to the importation of prescription drugs. H.R. 3108, the Medication Therapy Management Benefits Act, as related to an expanded MTM program in the Medicare Part D program. H.R. 3200, America's Affordable Health Choices Act of 2009, related to changes in pharmacy Medicaid reimbursement and the role of pharmacy and pharmacists in healthcare reform. H.R. 3663, as related to the delay of pharmacy accreditation requirements under the Medicare DME Program. S.1383, Dextromethorphan Abuse Reduction Act, as related to the abuse of dextromethorphan. S.___, Americas Healthy Future Act of 2009, related to changes in pharmacy Medicaid reimbursement and the role of pharmacy and pharmacists in healthcare reform. Various issues related to the role of pharmacy and pharmacists in healthcare reform, including pharmacy services in the Medicare program.
Client expense: $720,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Consumer Product Safety Commission (CPSC), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, White House Office
2009 · second_quarter · Pharmacy
H.R.1/S.350, the American Recovery and Reinvestment Act, related to health information technology and state Medicaid programs. H.R. 1259, the Dextromethorphan Distribution Act, as related to the abuse of dextromethorphan. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, as related to the approval of generic biopharmaceuticals. S.726, Promoting Innovation and Access to Life-Saving Medicine Act, as related to the approval of generic biopharmaceuticals. H.R.1450, Counterfeit Drug Prevention Act of 2009, as related to the prosecution of prohibited acts related to prescription drugs. H.R.759, Food and Drug Administration Globalization Act of 2009, as related to the safety of prescription drugs. H.R.1359/S.1292, Secure and Responsible Drug Disposal Act of 2009, as related to the role of pharmacy in the disposal of prescription drugs. H.R.616/S.511, Access to Durable Medical Equipment Act, related to the exemption of pharmacies from Medicare accreditation requirements. H.R.1970/S.956, Preserve Patient Access to Reputable DMEPOS Providers Act of 2009, as related to pharmacy exemption from the Medicare Part B surety bond requirement. H.R.1191/S.1336, Safe Drug Disposal Act of 2009, as related to the role of pharmacy in the disposal of prescription drugs. H.R. 2552, Medical Waste Management Act of 2009, as related to the role of pharmacy in the disposal of prescription drugs. H.R.3108, the Medication Therapy Management Benefits Act, related to expansion of the Medicare Part D medication therapy management benefit. S.525/H.R.1298/S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009, as related to the importation of prescription drugs. H.R.1548, Pathway for Biosimilars Act, as related to the approval of generic biopharmaceuticals. S. 1383, Dextromethorphan Abuse Reduction Act of 2009, as related to the abuse of dextromethorphan. H.R. 2923/S.256, Combat Methamphetamine Enhancement Act of 2009, as related to the abuse of methamphetamine. The Fair Medicaid Drug Payment Act, as related to pharmacy reimbursement for generic drugs in the Medicaid program. Various issues related to the role of pharmacy and pharmacists in healthcare reform, including pharmacy services in the Medicare program.
Client expense: $440,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Consumer Product Safety Commission (CPSC), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, White House Office
2009 · first_quarter · Pharmacy
**see addendum page Importation of prescription drugs (S. 525/H.R. 1298) RX Pedigree Methamphetamine/Pseudoephedrine Regulation (S. 256) Dextromethorphan Regulation (HR. 1259) Counterfeit Drugs (H.R. 1450) Import Safety (H.R. 759) FDA Food Safety Modernization Act (S. 510)
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Pharmacy
Importation of prescription drugs (S. 525/H.R. 1298); Import Safety (H.R. 759); Rx Pedigree; Counterfeit Drugs (H.R. 1450); Methamphetamine/Pseudoephedrine Regulation (S. 256); Dextromethorphan Regulation (H.R. 1259)
Client expense: $220,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Pharmacy
H.R.1, the American Recovery and Reinvestment Act, as related to health information technology and state Medicaid programs. H.R. 1259, the Dextromethorphan Distribution Act, as related to the abuse of dextromethorphan. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, as related to the approval of generic biopharmaceuticals. S. 726, Promoting Innovation and Access to Life-Saving Medicine Act, as related to the approval of generic biopharmaceuticals. H.R. 1450, Counterfeit Drug Prevention Act of 2009, as related to the prosecution of prohibited acts related to prescription drugs. H.R.759, Food and Drug Administration Globalization Act of 2009, as related to the safety of prescription drugs. H.R. 1359, Secure and Responsible Drug Disposal Act of 2009, as related to the role of pharmacy in the disposal of prescription drugs. H.R.616/S.511, Access to Durable Medical Equipment Act, related to the exemption of pharmacies from Medicare accreditation requirements. The Fair Medicaid Drug Payment Act, as related to pharmacy reimbursement in the Medicaid program. Various issues related to the role of pharmacy and pharmacists in healthcare reform, including pharmacy services in the Medicare program.
Client expense: $440,000 · Firm income: Not reported
| Republican |
| IN |
Government targets: Centers For Medicare and Medicaid Services (CMS), Consumer Product Safety Commission (CPSC), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, White House Office